A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients

Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2019
This article has no abstract
Epistemonikos ID: 66e95003e7875681eee8e5b995634e885fa4b410
First added on: Apr 09, 2025